VYNE Therapeutics (NASDAQ:VYNE) Raised to “Hold” at Wall Street Zen

VYNE Therapeutics (NASDAQ:VYNE) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $4.50.

VYNE Therapeutics Price Performance

NASDAQ VYNE opened at $0.57 on Monday. VYNE Therapeutics has a 1-year low of $0.28 and a 1-year high of $2.94. The business has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $0.45. The stock has a market capitalization of $19.11 million, a PE ratio of -0.74 and a beta of 2.02.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%.The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.13 million. On average, analysts anticipate that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

Institutional Trading of VYNE Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP purchased a new position in shares of VYNE Therapeutics during the third quarter valued at approximately $285,000. Shay Capital LLC bought a new stake in shares of VYNE Therapeutics during the 3rd quarter worth approximately $165,000. Two Sigma Investments LP purchased a new position in VYNE Therapeutics during the 3rd quarter valued at $74,000. Boothbay Fund Management LLC bought a new position in VYNE Therapeutics in the 2nd quarter valued at $176,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares during the period. 83.78% of the stock is owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.